| Project/Area Number |
15K20962
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
Applied pharmacology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Uchida Satoshi 東京大学, 大学院工学系研究科(工学部), 特任助教 (20710726)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | mRNA医薬 / 高分子ミセル / 遺伝子治療 / アポトーシス / 虚血性疾患 / mRNA導入 / 下肢虚血性疾患 / ナノミセル / mRNAデリバリー / 抗アポトーシス因子 |
|---|
| Outline of Final Research Achievements |
Introduction of pro-survival gene is an attractive strategy for treatment of ischemic diseases, and mRNA therapeutics is a safe and promising methodology for this purpose. While mRNA is subjected to nuclease degradation soon after in vivo delivery, we successfully solved this issue by encapsulating mRNA into biocompatible polyplex micelles. Then, we attempted treatment of hind limb ischemia by delivering mRNA encoding myr-Akt, a pro-survival factor, using polyplex micelles. The treatment resulted in significant recovery of blood flow in mouse hind limb. The mRNA-based pro-survival factor introduction is a promising strategy for the treatment of various diseases accompanying enhanced cell death, including ischemic diseases.
|
